Tag Archives: Prescription Drugs

A Billion Here, A Billion There: Selectively Disclosing Actual Generic Drug Prices Would Save Real Money

Selectively disclosing de-identified information on generic ingredient costs would enable health plans to negotiate reduced reimbursements to retail pharmacies for generic drugs.

September 12, 2017

Insurers Can Reduce Drug Prices, If Policymakers Let Them

Whilst decrying rapid increases in drug spending and prices, elected officials have actually made it increasingly difficult for insurers to do anything about it. Insurers want to constrain drug companies' pricing power, however numerous policies enacted in the name of facilitating patient...

July 14, 2016

Does A ‘One-Size-Fits-All’ Formulary Policy Make Sense?

The rapid growth in the use of step therapy policies in recent years---from 27 percent in 2005 to 73 percent in 2013 among employers---indicates a misunderstanding about the direct and indirect harms of this approach.

June 2, 2016

CMS White Paper Examines The ACA Risk Adjustment Methodology (Update)

On March 31, 2016, the Centers for Medicare and Medicaid Services will hold a public meeting to discuss potential changes to its Affordable Care Act risk adjustment program. On March 24, CMS published a White Paper describing its current risk adjustment program and options for modifying it.

March 29, 2016

HHS Marks Sixth Anniversary Of Affordable Care Act (Update)

March 23, 2016 marks the sixth anniversary of the signing of the Affordable Care Act. On March 22, the HHS ASPE released a report on Health Care Spending Growth and Federal Policy under the ACA. Also, an update on problems with and possible improvements to the small employer tax credit.

March 22, 2016

What Accounts For The Lower Growth In Health Care Spending?

Several recent studies have examined the factors accounting for the recent slowdown in growth in real per capita health care spending. Understanding the relative role of two factors, the recession and other structural changes, is important in determining whether the slowdown is temporary or...

February 18, 2016

How Much Does Congress Care About Drug Prices? Less Than It Should

Per-capita prescription drug spending in the United States increased by 12.2 percent in 2014. However, despite indications of renewed public attention to the rising cost of prescription drugs, Congress has actually paid little attention to and spent scant time on this issue in recent years.

January 13, 2016

The Impact Of New Hepatitis C Drugs On National Health Spending

According to data just released by CMS, health spending grew by 5.3 percent in 2014, ending the five-year run of record low growth rates in national health spending. The new hepatitis C drugs have had a significant impact on growth rates in spending on prescription drugs and on national health...

December 7, 2015

Prescription Drugs And The Slowdown In Health Care Spending

Several studies have examined the underlying sources for the recent slowdown in health care spending. However, they do not account for the full decline in spending, or raise questions about the pattern and timing of the slowdown.

November 18, 2015

How Government Policy Promotes High Drug Prices

US law governing prescription pharmaceutical markets gives every new drug a long-term monopoly that prohibits competition. High prices and slow innovation cycles are the inevitable result and will remain so unless Congress makes fundamental changes in existing law.

October 29, 2015